<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049529</url>
  </required_header>
  <id_info>
    <org_study_id>2005/3603/72</org_study_id>
    <secondary_id>2005/1/I/193</secondary_id>
    <nct_id>NCT01049529</nct_id>
  </id_info>
  <brief_title>Effect of Docosahexaenoic Acid on the Inflammatory Response and Clinical Outcomes From Surgical Patients</brief_title>
  <acronym>DHA-IRCO</acronym>
  <official_title>Efecto Modulador de la Administracion Del Acido Docosahexaenoico Sobre la Respuesta Inflamatoria, la evolución Clinica y el Estado Nutricional de Neonatos Sometidos a cirugía</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Coordinación de Investigación en Salud, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Coordinación de Investigación en Salud, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate if enteral docosahexaenoic acid (DHA) administration
      attenuates the inflammatory cytokines and improve clinical outcomes in neonates who underwent
      cardiovascular surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe sepsis and organ failure are leading causes of death in surgical patients. Several
      studies indicate that a causal relationship exists between the surgical or traumatic injury
      and the predisposition to develop septic/infectious complications and multiple organ failure;
      this is attributable to uncontrolled inflammatory response. Since neonates have an immature
      immune system, they are in a higher risk to develop uncontrolled inflammatory response and
      adverse clinical outcomes.

      N-3 long chain polyunsaturated fatty acids (L-PUFAs) such as docosapentaenoic and
      docosahexaenoic acids (EPA and DHA) have been shown to reduce the inflammatory response by
      reducing cytokines, infection rates and length of hospitalization in patients with abdominal
      surgery. Therefore, acute and enteral administration of DHA may improve clinical outcomes in
      neonates with cardiovascular surgery
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory response measured by cytokines IL-1, IL-6, TNF-alfa, IL-10 e IL-1ra and clinical outcomes assessed as frequency of severe sepsis, respiratory and cardiovascular dysfunction.</measure>
    <time_frame>During the hospital stay, two weeks in average</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Severe Sepsis</condition>
  <condition>Organ Dysfunction Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group is receiving sunflower oil (the excipient for DHA)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DHA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group is receiving the docosahexaenoic acid (DHA) supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Docosahexaenoic acid</intervention_name>
    <description>DHA have oil form. Each neonate is receiving 75 mg/kg/day of DHA in 188 uL/kg/day in two doses per day, since two days before surgery and over six days following cardiovascular surgery</description>
    <arm_group_label>DHA group</arm_group_label>
    <other_name>n-3 LC-PUFAs</other_name>
    <other_name>omega 3 fatty acids</other_name>
    <other_name>Long chain polyunsaturated fatty acids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo have oil form. Each neonate is receiving 188uL/kg/day of sunflower oil as placebo in two doses per day, since two days before surgery and over six days following cardiovascular surgery</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Life's DHA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Authorization from both parents for recruiting of the neonate into the study with
             consent signed form after the purpose and procedures have been explained

          -  Gestational age older than 32 weeks

          -  Adequate weight for gestational age

          -  Gastrointestinal tract that allows tolerate the doses of DHA or placebo

          -  No signs of Systemic Inflammatory Response Syndrome before the surgery as fever &gt;38
             degrees C or hypothermia &lt;36 degrees C, or leukocytosis &gt;19,500 cells/cubic mm or &lt;
             5000 cells/cubic mm or &gt; 10% immature forms.

        Exclusion Criteria:

          -  Fasting for more than two days after surgery

          -  Discharge to other hospital outside the metropolitan area

          -  Parents who decide to decline of the study

          -  Patients who necessitate cardiovascular bypass
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>45 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariela Bernabe-Garcia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Mexicano del Seguro Social</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unit of Research in Nutrition, Pediatric Hospital, Instituto Mexicano del Seguro Social</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>López-Alarcón M, Bernabe-García M, Del Prado M, Rivera D, Ruiz G, Maldonado J, Villegas R. Docosahexaenoic acid administered in the acute phase protects the nutritional status of septic neonates. Nutrition. 2006 Jul-Aug;22(7-8):731-7. Epub 2006 Jun 5.</citation>
    <PMID>16750345</PMID>
  </reference>
  <reference>
    <citation>López-Alarcón M, Bernabe-García M, del Valle O, González-Moreno G, Martínez-Basilea A, Villegas R. Oral administration of docosahexaenoic acid attenuates interleukin-1β response and clinical course of septic neonates. Nutrition. 2012 Apr;28(4):384-90. doi: 10.1016/j.nut.2011.07.016. Epub 2011 Nov 12.</citation>
    <PMID>22079797</PMID>
  </reference>
  <results_reference>
    <citation>Bernabe-Garcia M, Lopez-Alarcon M, Villegas-Silva R, Mancilla-Ramirez J, Rodriguez-Cruz M, Maldonado-Hernandez J, Chavez-Rueda KA, Blanco-Favela F, Espinoza-Garcia L, Lagunes-Salazar S. Beneficial Effects of Enteral Docosahexaenoic Acid on the Markers of Inflammation and Clinical Outcomes of Neonates Undergoing Cardiovascular Surgery: An Intervention Study. Ann Nutr Metab. 2016;69(1):15-23. doi: 10.1159/000447498. Epub 2016 Jul 9.</citation>
    <PMID>27394149</PMID>
  </results_reference>
  <results_reference>
    <citation>Bernabe-Garcia M, López-Alarcon M, Salgado-Sosa A, Villegas-Silva R, Maldonado-Hernandez J, Rodríguez-Cruz M, Rivas-Ruiz R, Chavez-Sanchez L, Blanco-Favela FA, Mancilla-Ramirez J, Gordillo-Alvarez V, Madrigal-Muñiz O. Enteral Docosahexaenoic Acid Reduces Analgesic Administration in Neonates Undergoing Cardiovascular Surgery. Ann Nutr Metab. 2016;69(2):150-160. Epub 2016 Nov 2.</citation>
    <PMID>27806350</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Coordinación de Investigación en Salud, Mexico</investigator_affiliation>
    <investigator_full_name>Mariela Bernabe García</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Docosahexaenoic acid</keyword>
  <keyword>n-3 Long Chain Polyunsaturated Fatty Acids</keyword>
  <keyword>omega 3 fatty acids</keyword>
  <keyword>neonates</keyword>
  <keyword>clinical outcomes</keyword>
  <keyword>critically ill patients</keyword>
  <keyword>Inflammatory and antiinflammatory cytokines</keyword>
  <keyword>Length of intensive care stay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

